PMZ 2123

Drug Profile

PMZ 2123

Alternative Names: BQ 123

Latest Information Update: 05 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Midwestern University
  • Developer Banyu; Pharmazz; University of Glasgow; Western Infirmary
  • Class
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diabetic ketoacidosis
  • Discontinued Arrhythmias; Cerebral ischaemia; Diabetic complications; Heart failure; Hypertension; Hypertension in pregnancy; Myocardial ischaemia; Peripheral vascular disorders; Stress ulcer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 29 Nov 2016 Pharmazz receives patent allowance for PMZ 2123 in Canada
  • 20 Sep 2016 Phase-I clinical trials in Diabetic ketoacidosis in USA prior to September 2016 (Parenteral) (Pharmazz pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top